{"id":612305,"date":"2022-08-17T17:26:02","date_gmt":"2022-08-17T17:26:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=612305"},"modified":"2022-08-17T17:26:02","modified_gmt":"2022-08-17T17:26:02","slug":"type-1-diabetes-pipeline-involves-80-key-companies-continuously-working-towards-developing-100-type-1-diabetes-treatment-therapies-as-per-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/type-1-diabetes-pipeline-involves-80-key-companies-continuously-working-towards-developing-100-type-1-diabetes-treatment-therapies-as-per-delveinsight_612305.html","title":{"rendered":"Type 1 Diabetes pipeline involves 80+ key companies continuously working towards developing 100+ Type 1 Diabetes treatment therapies, as per DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1660705163.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Type 1 Diabetes pipeline involves 80+ key companies continuously working towards developing 100+ Type 1 Diabetes treatment therapies, as per DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1660705163.jpeg\" alt=\"Type 1 Diabetes pipeline involves 80+ key companies continuously working towards developing 100+ Type 1 Diabetes treatment therapies, as per DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Type 1 Diabetes pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s&nbsp;<strong>&#8216;<\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/type-1-diabetes-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\"><strong>Type 1 Diabetes Pipeline Insight 2022<\/strong><\/a><strong>&#8216;<\/strong>&nbsp;report provides comprehensive global coverage of available, marketed, and pipeline type 1 diabetes therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the type 1 diabetes pipeline domain.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Type 1 Diabetes Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>DelveInsight&rsquo;s type 1 diabetes pipeline report depicts a robust space with<strong>&nbsp;80+&nbsp;<\/strong>companies working to develop&nbsp;<strong>100+&nbsp;<\/strong>pipeline therapies for type 1 diabetes treatment.<\/li>\n<li>Key type 1 diabetes companies such as&nbsp;<strong>Landos Biopharma, Zealand Pharma,&nbsp; Prevention Bio, Histogen, Vertex Pharmaceuticals, Panbela Therapeutics, Novartis, ImCyse, , Tolerion, Avotres, REMD Biotherapeutics, Novo Nordisk, Eledon Pharmaceuticals, Avotres, Eli Lilly and Company, GEROPHARM, Regeneron Pharmaceuticals, Diamyd Medical, NextCell Pharma, Novartis, ViaCyte, Op-T LLC, Dompe Farmaceutici, ILTOO Pharma, Throne Biotechnologies, Oramed, Adocia, Imcyse, Janssen Biotech, Xeris Pharmaceuticals, Zealand Pharma, Jaguar Gene Therapy,&nbsp; SQZ Biotech, Enthera,&nbsp;<\/strong>and others are evaluating new type 1 diabetes drugs to improve the&nbsp;treatment landscape.<\/li>\n<li>Promising type 1 diabetes pipeline therapies in various stages of development include<strong>&nbsp;LABP 111, TTP 399, Teplizumab, Emricasan, VX 880,&nbsp; Encapsulated islet cell program, Eflornithine oral, Iscalimab, IMCY 0098, AT-1501, TOL 3021, AVT001, Volagidemab, NNC0363 0845, NNC0268-0965, LY 3209590, GP40071, Autoimmune diabetes vaccine, ProTrans, MHS 552, VC-02, OPT101, VC-01, Ladarixin, Aldesleukin, Stem Cell Educator therapy, ORMD-0801, ADO09, IMCY-0098, Glucagon intranasal, Golimumab, LY 900027, PRAM9JAG301,&nbsp; Dasiglucagon, SQZ TAC research program, Ent001,&nbsp;<\/strong>and others.<\/li>\n<li>In July 2022,<strong>&nbsp;Vertex Pharmaceuticals&nbsp;<\/strong>announced that the company has entered into a definitive agreement under which Vertex will acquire&nbsp;<strong>ViaCyte<\/strong>, a privately held biotechnology company focused on delivering novel stem cell-derived cell replacement therapies as a functional cure for&nbsp;<strong>type 1 diabetes (T1D),&nbsp;<\/strong>for $320 million in cash.<\/li>\n<li>In June 2022,<strong>&nbsp;Vertex Pharmaceuticals&nbsp;<\/strong>announced that the U.S. Food and Drug Administration (FDA) lifted the clinical hold placed on the Phase I\/II clinical trial of<strong>&nbsp;VX-880,<\/strong>&nbsp;an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with&nbsp;<strong>type 1 diabetes (T1D)&nbsp;<\/strong>with impaired hypoglycemia awareness and severe hypoglycemia.<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li>In April 2022,&nbsp;<strong>AVM Biotechnology<\/strong>&nbsp;received&nbsp;Small Business Innovation Research (SBIR) award of $1.6m from the National Institute of Diabetes and Digestive Kidney Disease (NIDDK) to study its small molecule,&nbsp;<strong>AVM0703<\/strong>, for reversing Type 1 diabetes (T1D). The latest grant will permit the company to carry out further research into using AVM0703 as a single agent and as a combination treatment for reversing recent onset and established T1D.<\/li>\n<li>In May 2022,<strong>&nbsp;Sernova and Evotec<\/strong>&nbsp;are pleased to announce an exclusive global strategic partnership to develop a best-in-class cell therapy treatment for people living with insulin-dependent diabetes. The partnership provides Sernova a global exclusive option to license Evotec&rsquo;s iPSC-based beta cells for use in treating both&nbsp;<strong>type 1 and type 2 diabetes<\/strong>. In addition to entering into the collaboration agreement, Evotec has made a strategic equity investment of<strong>&nbsp;&euro;15M and will make a further investment of &euro;5M<\/strong>.<\/li>\n<li>In March 2022,&nbsp;<strong>Jaguar Gene Therapy announced Samsung Ventures,&nbsp;<\/strong>an investment corporation established to promote the development of new technologies, and the JDRF T1D Fund, a venture philanthropy fund devoted to finding and funding the best cure-oriented therapies for T<strong>ype 1 diabetes (T1D),<\/strong>&nbsp;have invested in the company.<\/li>\n<li>In January 2022,<strong>&nbsp;Remedium Bio&nbsp;<\/strong>announced it has entered into a Sponsored Research Agreement with the University of Massachusetts Boston to complete pre-clinical efficacy studies on&nbsp;<strong>Type 1 and Type 2 Diabetes pipeline candidates<\/strong>. The collaboration to evaluate platform technology for the treatment of Diabetes, with translational potential to the broader Remedium pipeline of single-injection potentially disease-modifying gene therapies.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" src=\"https:\/\/www.abnewswire.com\/uploads\/2298685b58f722ed52c58e5a4196b561.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Request a sample and discover the recent advances in type 1 diabetes treatment drugs @&nbsp;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/type-1-diabetes-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Type 1 Diabetes Clinical trial Outlook<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">The type 1 diabetes pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage type 1 diabetes products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the type 1 diabetes pipeline landscape.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Type 1 Diabetes Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Type 1 diabetes mellitus (T1DM) is an autoimmune disease that causes the loss of insulin-producing pancreatic beta cells. Insulin is a necessary anabolic hormone that influences glucose, lipid, protein, and mineral metabolism, as well as growth. The exact type 1 diabetes causes are unknown. T1DM develops in three phases. Stage 1 is asymptomatic and is distinguished by normal fasting glucose, normal glucose tolerance, and the presence of more than or equivalent to two pancreatic autoantibodies.<\/p>\n<p style=\"text-align: justify;\">Type 1 diabetes symptoms might occur unexpectedly and include frequent urine, weight loss, blurry vision, tiredness, weakness, and others. The blood test is the most common method for type 1 diabetes diagnosis.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Find out more about type 1 diabetes treatment drugs @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/type-1-diabetes-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\"><strong>Type 1 Diabetes Medications<\/strong><\/a><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>A snapshot of the Type 1 Diabetes Pipeline Drugs mentioned in the report:<\/strong><\/p>\n<table style=\"width: 415px;\" border=\"1\" cellspacing=\"0\" cellpadding=\"10\">\n<tbody>\n<tr>\n<td valign=\"top\" width=\"151\">\n<p><strong>Drugs<\/strong><\/p>\n<\/td>\n<td valign=\"top\" width=\"265\">\n<p><strong>Company<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\" width=\"151\">\n<p>Teplizumab<\/p>\n<\/td>\n<td valign=\"top\" width=\"265\">\n<p>Prevention Bio<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\" width=\"151\">\n<p>Dasiglucagon<\/p>\n<\/td>\n<td valign=\"top\" width=\"265\">\n<p>Zealand Pharma<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\" width=\"151\">\n<p>AT-1501<\/p>\n<\/td>\n<td valign=\"top\" width=\"265\">\n<p>Eledon Pharmaceuticals<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\" width=\"151\">\n<p>AVT001<\/p>\n<\/td>\n<td valign=\"top\" width=\"265\">\n<p>Avotres<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\" width=\"151\">\n<p>IMCY-0098<\/p>\n<\/td>\n<td valign=\"top\" width=\"265\">\n<p>ImCyse<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\" width=\"151\">\n<p>Iscalimab<\/p>\n<\/td>\n<td valign=\"top\" width=\"265\">\n<p>Novartis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\" width=\"151\">\n<p>Emricasan<\/p>\n<\/td>\n<td valign=\"top\" width=\"265\">\n<p>Histogen<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\" width=\"151\">\n<p>VX-880<\/p>\n<\/td>\n<td valign=\"top\" width=\"265\">\n<p>Vertex Pharmaceuticals<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\" width=\"151\">\n<p>NNC0363 0845<\/p>\n<\/td>\n<td valign=\"top\" width=\"265\">\n<p>Novo Nordisk<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\" width=\"151\">\n<p>Eflornithine<\/p>\n<\/td>\n<td valign=\"top\" width=\"265\">\n<p>Panbela Therapeutics<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\" width=\"151\">\n<p>LABP 111<\/p>\n<\/td>\n<td valign=\"top\" width=\"265\">\n<p>Landos Biopharma<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Learn more about the novel and emerging type 1 diabetes pipeline therapies @&nbsp;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/type-1-diabetes-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Type 1 Diabetes Clinical Trials<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Type 1 Diabetes Therapeutics Assessment<\/strong><\/p>\n<p style=\"text-align: justify;\">The&nbsp;<strong>type 1 diabetes pipeline<\/strong>&nbsp;report proffers an integral view of the type 1 diabetes emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Type 1 Diabetes Pipeline Report&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Coverage<\/strong>:&nbsp;Global<\/li>\n<li><strong>Therapeutic Assessment By Product Type:&nbsp;<\/strong>Mono, Combination, Mono\/Combination<\/li>\n<li><strong>Therapeutic Assessment By Clinical Stages:&nbsp;<\/strong>Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/li>\n<li><strong>Therapeutics Assessment<\/strong>&nbsp;<strong>By Route of Administration:<\/strong>&nbsp;Intravenous, Oral, Subcutaneous<\/li>\n<li><strong>Therapeutics Assessment<\/strong>&nbsp;<strong>By Molecule Type<\/strong>: Cell therapy, Peptide, Small molecule, Polymer, Gene therapy<\/li>\n<li><strong>Therapeutics Assessment<\/strong>&nbsp;<strong>By Mechanism of Action:&nbsp;<\/strong>CD3 antigen inhibitors, Apoptosis inhibitors, Caspase inhibitors, Pancreatic beta cell replacements, Glucagon receptor agonists, LANCL2 protein stimulants, Ornithine decarboxylase stimulants, Immunostimulants and Cytotoxic T lymphocyte stimulants,<\/li>\n<li><strong>Key Type 1 Diabetes Pipeline Therapies<\/strong>:&nbsp;<strong>&nbsp;<\/strong>LABP 111, TTP 399, Teplizumab, Emricasan, VX 880,&nbsp; Encapsulated islet cell program, Eflornithine oral, Iscalimab, IMCY 0098, AT-1501, TOL 3021, AVT001, Volagidemab, NNC0363 0845, NNC0268-0965, LY 3209590, GP40071, Autoimmune diabetes vaccine , ProTrans, MHS 552, VC-02, OPT101, VC-01, Ladarixin, Aldesleukin , Stem Cell Educator therapy, ORMD-0801, ADO09, IMCY-0098, Glucagon intranasal, Golimumab, LY 900027, PRAM9JAG301,&nbsp; Dasiglucagon, SQZ TAC research program, Ent001 and others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Dive deep into rich insights for new drugs for type 1 diabetes treatment, visit @&nbsp;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/type-1-diabetes-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">FDA-approved Type 1 Diabetes Drugs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<table style=\"width: 545px;\" border=\"1\" cellspacing=\"0\" cellpadding=\"10\">\n<tbody>\n<tr>\n<td valign=\"top\">\n<p>1.<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Type 1 Diabetes Pipeline Report Introduction<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>2.<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Type 1 Diabetes Pipeline Report Executive Summary<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>3.<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Type 1 Diabetes Pipeline: Overview<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>4.<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Analytical Perspective In-depth Commercial Assessment<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>5.<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Type 1 Diabetes Pipeline Therapeutics<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>6.<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Type 1 Diabetes Pipeline: Late Stage Products (Pre-registration)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>7.<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Teplizumab: Prevention Bio<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>8.<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Type 1 Diabetes Pipeline: Late Stage Products (Phase III)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>9.<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Dasiglucagon: Zealand Pharma<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>10.<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Type 1 Diabetes Pipeline: Mid Stage Products (Phase II)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>11.<\/p>\n<\/td>\n<td valign=\"top\">\n<p>IMCY-0098: ImCyse<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>12<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Type 1 Diabetes Pipeline: Early Stage Products (Phase I)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>13.<\/p>\n<\/td>\n<td valign=\"top\">\n<p>NNC0363 0845: Novo Nordisk<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>14.<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Type 1 Diabetes Pipeline Therapeutics Assessment<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>15.<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Inactive Products in the Type 1 Diabetes Pipeline<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>16.<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Company-University Collaborations (Licensing\/Partnering) Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>17.<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Key Companies<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>18.<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Key Products in the Type 1 Diabetes Pipeline<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>19.<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Unmet Needs<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>20.<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Market Drivers and Barriers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>21.<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Future Perspectives and Conclusion<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>22.<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Analyst Views<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>23.<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Appendix<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=type-1-diabetes-pipeline-involves-80-key-companies-continuously-working-towards-developing-100-type-1-diabetes-treatment-therapies-as-per-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/type-1-diabetes-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/type-1-diabetes-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/type-1-diabetes-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=type-1-diabetes-pipeline-involves-80-key-companies-continuously-working-towards-developing-100-type-1-diabetes-treatment-therapies-as-per-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Type 1 Diabetes pipeline DelveInsight&rsquo;s&nbsp;&#8216;Type 1 Diabetes Pipeline Insight 2022&#8216;&nbsp;report provides comprehensive global coverage of available, marketed, and pipeline type 1 diabetes therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/type-1-diabetes-pipeline-involves-80-key-companies-continuously-working-towards-developing-100-type-1-diabetes-treatment-therapies-as-per-delveinsight_612305.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,413,404],"tags":[],"class_list":["post-612305","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Services","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/612305","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=612305"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/612305\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=612305"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=612305"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=612305"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}